Published on:

Investor Complaints: Galmed Pharmaceuticals, Ltd (NASDAQ: GLMD)

The securities and investment fraud law firm Fitapelli Kurta is interested in speaking to investors who have lost money investing in Galmed Pharmaceuticals, Ltd (NASDAQ: GLMD).

According to MarketWatch, Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing “therapeutics for liver diseases and gallstones.” It trades on the NASDAQ exchange under GLMD.

Galmed Pharmaceuticals is headquartered in Tel Aviv, Israel. Chaim Hurwitz has held the position of Chairman since 2011; Allen Baharaff has been President, Chief Executive Officer, and Director since 2000; Josh Blacher has been Chief Financial Officer since 2015; Dr. Maya Halperin has been Chief Medical Officer and Director since 2011; George Tonelli has been Vice President of Clinical Operations since 2015.

In July 2015 GLMD announced it entered into a Research, Option, and License Agreement with One Way Liver Genomics for the development of a “non-invasive, blood-based companion diagnostic tool.” Under the agreement, GLMD and One Way Liver Genomics will work together to develop a test that “could potentially predict therapeutic responses to AramcholTM, Galmed’s once-daily, oral therapy for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH.”

In May 2013 GLMD announced its first quarter financial results, reporting a net loss of $2.5 million, or $0.22/share, for the quarter ending in March 2015. This same period in the previous year saw a net loss of $2.2 million, or $0.27/share. GLMD additionally saw a financial income of $0.04 million for the quarter ending in March 2015, which “resulted primarily from interest income earned on short-term deposit and marketable securities.” Galmed Pharmaceuticals has scheduled its second quarter conference call and webcast for August 13, 2015.

If you have lost money investing in Galmed Pharmaceuticals (GLMD), call the securities and investment fraud law firm Fitapelli Kurta at 877-238-4175 for a free consultation. You may be able to recover your losses. All cases are taken on contingency, which means Fitapelli Kurta only gets paid if and when you recover money.  Time to file your claim may be limited, so we encourage you to avoid delay. Call 877-238-4175 now to speak to an attorney for free.